Globus Medical (NYSE:GMED) Stock Gets Price Target Reduction from Canaccord Genuity Group

Globus Medical (NYSE:GMED) had its target price lowered by Canaccord Genuity Group from $115.00 to $105.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the medical device company’s stock. Canaccord Genuity Group‘s price objective suggests a potential upside of 45.55% from the stock’s current price.

Other research analysts also recently issued reports about the company. BMO Capital Markets downgraded Globus Medical from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $94.00 to $78.00 in a report on Friday. Needham & Company LLC dropped their price target on Globus Medical from $117.00 to $100.00 and set a “buy” rating on the stock in a research report on Friday. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 10th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research report on Friday, October 9th. Finally, UBS Group initiated coverage on shares of Globus Medical in a report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $96.46.

Globus Medical Stock Down 11.4%

NYSE GMED traded down $9.30 during trading hours on Friday, reaching $72.14. The company’s stock had a trading volume of 6,017,490 shares, compared to its average volume of 1,501,928. Globus Medical has a 1 year low of $70.74 and a 1 year high of $101.40. The company has a market capitalization of $9.69 billion, a price-to-earnings ratio of 18.43, a PEG ratio of 1.40 and a beta of 0.98. The firm’s 50-day moving average price is $77.44 and its 200-day moving average price is $83.29.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.03. The business had revenue of $763.72 million during the quarter, compared to analysts’ expectations of $792.39 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The firm’s revenue for the quarter was down .7% compared to the same quarter last year. During the same quarter last year, the business posted $1.18 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities research analysts anticipate that Globus Medical will post 4.99 EPS for the current fiscal year.

Insider Activity at Globus Medical

In other news, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the sale, the director directly owned 25,000 shares of the company’s stock, valued at $2,176,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James Tobin sold 30,000 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the sale, the director directly owned 15,000 shares in the company, valued at approximately $1,118,700. The trade was a 66.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 60,000 shares of company stock worth $4,838,400. 18.38% of the stock is owned by company insiders.

Institutional Trading of Globus Medical

Institutional investors and hedge funds have recently made changes to their positions in the business. Sanctuary Advisors LLC boosted its position in shares of Globus Medical by 2.3% during the 1st quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock worth $570,000 after acquiring an additional 151 shares in the last quarter. Summitry LLC boosted its stake in shares of Globus Medical by 2.6% during the 1st quarter. Summitry LLC now owns 8,205 shares of the medical device company’s stock worth $707,000 after acquiring an additional 211 shares in the last quarter. Central Pacific Bank Trust Division grew its holdings in shares of Globus Medical by 7.8% in the 3rd quarter. Central Pacific Bank Trust Division now owns 3,057 shares of the medical device company’s stock worth $229,000 after acquiring an additional 220 shares during the period. Arizona State Retirement System increased its holdings in Globus Medical by 0.8% during the 2nd quarter. Arizona State Retirement System now owns 31,077 shares of the medical device company’s stock valued at $2,455,000 after acquiring an additional 252 shares in the last quarter. Finally, Angeles Wealth Management LLC increased its holdings in Globus Medical by 5.0% during the 2nd quarter. Angeles Wealth Management LLC now owns 5,894 shares of the medical device company’s stock valued at $466,000 after acquiring an additional 280 shares in the last quarter. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter EPS was $1.23, above the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, providing a potential shareholder-return boost. Q3 results and buyback announcement
• Positive Sentiment: Wells Fargo raised its price target to $100 and maintained an Overweight rating. Globus’s acquisition of Synaptive Medical also expands its cranial-neurosurgery offerings, though its financial impact remains to be seen. Synaptive acquisition
• Neutral Sentiment: Analyst actions were mixed: Needham lowered its target to $100 but kept a Buy rating, while Director Ann Rhoads sold 5,000 shares. The sale alone does not establish a change in the company’s outlook. Insider sale report
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million estimate and fell 0.7% year over year. 2026 revenue guidance of $3.1 billion is below the $3.2 billion consensus, while EPS guidance of $4.95–$5.05 is roughly in line with expectations. The company cited spine-launch delays and weak Nevro sales, and BMO downgraded GMED to Market Perform while cutting its target to $78. Earnings-call outlook and guidance

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.